Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
SMC (1243/17)
04/12/2024
Indication
For treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.
Therapeutic Area
Skin
Status Description
Routinely available in line with national guidance
Formulation
-
Comments
Refer to pathway or local board guidelines for preferred formulation
Link to Advice
Advice Published
12/06/2017
SMC Submission Type
Abbreviated
SMC Status
Accepted